Cargando…

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier

A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could lead to a more personalized and efficient treatment regime, and enable identification of ADA-p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kharlamova, Nastya, Hermanrud, Christina, Dunn, Nicky, Ryner, Malin, Hambardzumyan, Karen, Vivar Pomiano, Nancy, Marits, Per, Gjertsson, Inger, Saevarsdottir, Saedis, Pullerits, Rille, Fogdell-Hahn, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385065/ https://www.ncbi.nlm.nih.gov/pubmed/32793189 http://dx.doi.org/10.3389/fimmu.2020.01365

Ejemplares similares

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases
por: Kharlamova, Nastya, et al.
Publicado: (2021)

The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy
por: Dunn, Nicky, et al.
Publicado: (2020)

Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
por: Wincup, Chris, et al.
Publicado: (2022)

Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
por: Link, Jenny, et al.
Publicado: (2014)

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta
por: Ingenhoven, Kathleen, et al.
Publicado: (2017)

Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data
por: Barbulescu, Andrei, et al.
Publicado: (2022)

Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study
por: Mörck, Boel, et al.
Publicado: (2013)

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS
por: Andlauer, Till F. M., et al.
Publicado: (2020)

Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial
por: Levitsky, Adrian, et al.
Publicado: (2017)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Survivin Measurement improves Clinical Prediction of Transition From Arthralgia to RA—Biomarkers to Improve Clinical Sensitivity of Transition From Arthralgia to RA
por: Erlandsson, Malin C., et al.
Publicado: (2018)

Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register
por: Cagnotto, Giovanni, et al.
Publicado: (2020)

Tobacco as a Drug in Earlier English Medicine
por: Mullett, Charles F.
Publicado: (1940)

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
por: Hambardzumyan, Karen, et al.
Publicado: (2017)

Clinical Significance of Diabetes-Mellitus-Associated Antibodies in Rheumatoid Arthritis
por: Erlandsson, Malin C., et al.
Publicado: (2022)

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial
por: Hambardzumyan, Karen, et al.
Publicado: (2016)

Risk of Thyroxine-Treated Autoimmune Thyroid Disease Associated With Disease Onset in Patients With Rheumatoid Arthritis
por: Waldenlind, Kristin, et al.
Publicado: (2018)

Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?
por: Waldenlind, Kristin, et al.
Publicado: (2020)

Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control
por: Pullerits, Rille, et al.
Publicado: (2005)

Circulating resistin levels are early and significantly increased in deceased brain dead organ donors, correlate with inflammatory cytokine response and remain unaffected by steroid treatment
por: Pullerits, Rille, et al.
Publicado: (2015)

Bacteria and Host Interplay in Staphylococcus aureus Septic Arthritis and Sepsis
por: Jin, Tao, et al.
Publicado: (2021)

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
por: Lindgren, Ulrika, et al.
Publicado: (2022)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
por: Hambardzumyan, Karen, et al.
Publicado: (2015)

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
por: Faustini, Francesca, et al.
Publicado: (2022)

Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling
por: Pullerits, Rille, et al.
Publicado: (2008)

High Expression of STAT3 in Subcutaneous Adipose Tissue Associates with Cardiovascular Risk in Women with Rheumatoid Arthritis
por: Nadali, Mitra, et al.
Publicado: (2017)

Metabolic signature and proteasome activity controls synovial migration of CDC42(hi) CD14(+) cells in rheumatoid arthritis
por: Malmhäll-Bah, Eric, et al.
Publicado: (2023)

Brief Report: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi‐Biomarker Disease Activity Score as an Inclusion Criterion
por: van Vollenhoven, Ronald F., et al.
Publicado: (2015)

Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study
por: Tidblad, Liselotte, et al.
Publicado: (2022)

Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation
por: Oltean, Simona, et al.
Publicado: (2013)

Proactive measurement of infliximab drug levels in children with Crohn’s disease
por: Holland, Kathleen, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
por: Gordon, Benjamin L., et al.
Publicado: (2023)

Low Soluble Receptor for Advanced Glycation End Products Precedes and Predicts Cardiometabolic Events in Women With Rheumatoid Arthritis
por: Nadali, Mitra, et al.
Publicado: (2021)

Faster smooth muscle cell coverage in ultrathin-strut drug-eluting stent leads to earlier re-endothelialization
por: Hahn, Dongwoo, et al.
Publicado: (2023)

Inclusion body myositis with early onset: a population-based study
por: Lindgren, Ulrika, et al.
Publicado: (2023)

IGF1R signalling is a guardian of self-tolerance restricting autoantibody production
por: Erlandsson, Malin C., et al.
Publicado: (2022)

The effect of chemotherapeutic drugs on human B lymphocytes
por: Zirakzadeh, Ali, et al.
Publicado: (2013)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5nghh2rpaf0khbk136ml814ot6